Pharmafile Logo
Pharmafocus logo
Advanced Search

renal cell carcinoma

Showing 15 posts of 18 posts found.

Merck announces phase 3 LITESPARK-005 trial met primary endpoint

August 22, 2023
Research and Development Merck, Oncology, Welireg, belzutifan, clinical trial, renal cell carcinoma

Merck (known as MSD outside of the US and Canada) has shared topline results from its phase 3 LITESPARK-005 trial, …

News
eisa0008_web

Eisai releases new Phase 2 data for levatinib+everolimus combo in advanced kidney cancer

February 17, 2020
Research and Development, Sales and Marketing Cancer, Eisai, Kidney cancer, Lenvima, pharma, renal cell carcinoma

New Phase 2 data has been revealed for Eisai’s Lenvima (levatinib), delivered alongside Novartis’ everolimus, for the treatment of unresectable …

News
merckwindow_web

Keytruda scores EU approval in combination with Inlyta for first-line advanced renal cell carcinoma

September 4, 2019
Research and Development, Sales and Marketing EU, Europe, MSD, keytruda, pharma, renal cell carcinoma

The European Commission has awarded yet another authorisation in the region to MSD’s Keytruda, this time in combination with the …

News

Pfizer & Merck’s Inlyta combo becomes first FDA-approved anti-PD-L1 therapy for kidney cancer

May 15, 2019
Research and Development, Sales and Marketing FDA, Merck KGaA, Pfizer, inylta, pharma, renal cell carcinoma

The FDA has approved Bavencio (avelumab) in combination with Inlyta (axitinib) for the treatment of advanced renal cell carcinoma (RCC). …

News
merckwindow_web

MSD’s Keytruda combo therapy significantly improves survival in advanced renal cell carcinoma

February 18, 2019
Sales and Marketing Cancer, MSD, Merck Sutent, Pfizer, inlyta, keytruda, oncology, rcc, renal cell carcinoma

Merck & Co’s Keytruda (pembrolizumab) in combination with Pfizer’s Inlyta (axitinib) significantly extended the lives of those with advanced renal …

News
merck-keytruda

Keytruda + Inlyta combo beats Pfizer’s chemotherapy Sutent in renal cell carcinoma

February 12, 2019
Manufacturing and Production, Research and Development Cancer, MSD, Pfizer, inlyta, keytruda, pharma, renal cell carcinoma

New data has been revealed on the efficacy of MSD’s Keytruda (pembrolizumab) in combination with Pfizer’s Inlyta (axitinib), showing it …

News
roche_dark_0

Roche withdraws Tecentriq combo application in first-line renal cell carcinoma

November 19, 2018
Sales and Marketing Cancer, Roche, avastin, pharma, renal cell carcinoma, tecentriq

The EMA has revealed that Roche has chosen to withdraw its marketing application for immunotherapy Tecentriq (atezolizumab) in combination with …

News
ema_inside

EMA recommends two new treatments for advanced kidney cancer

July 22, 2016
Research and Development, Sales and Marketing EMA, Eisai, renal cell carcinoma

The European Medicines Agency (EMA) has recommended two new medicines for the treatment of advanced renal cell carcinoma, or kidney …

News
trials

Eisai granted additional indication for Lenvima in renal cell carcinoma

May 16, 2016
Sales and Marketing Eisai, additional indication, renal cell carcinoma

Eisai has announced that it has received approval from the US Food and Drug Administration (FDA) for an additional indication …

News
Eisai logo

FDA grants Eisai’s Lenvima priority review for kidney cancer

January 19, 2016
Manufacturing and Production Breakthrough Therapy Designation, Eisai, FDA, Kidney cancer, Lenvima, lenvatinib, priority review, renal cell carcinoma

The FDA has accepted Eisai’s supplemental New Drug Application (sNDA) for its anti-cancer agent Lenvima for use in the treatment …

News
Opdivo

Bristol-Myers Squibb notches kidney cancer first with Opdivo

September 28, 2015
Research and Development Afinitor, Bristol-Myers Squibb, Kidney cancer, advanced kidney cancer, everolimus, nivolumab, opdivo, renal cell carcinoma

Bristol-Myers Squibb has announced positive results from a Phase III study comparing Opdivo to Afinitor, the Novartis treatment that is …

News

FDA grants Opdivo breakthrough status for kidney cancer

September 18, 2015
Research and Development, Sales and Marketing BMS, Breakthrough Therapy Designation, Bristol-Myers Squibb, FDA, Kidney cancer, immuno-oncology, immunotherapy, nivolumab, opdivo, renal cell carcinoma

The FDA has given Bristol-Myers Squibb’s immuno-oncology drug Opdivo Breakthrough Therapy Designation as a kidney cancer treatment. The FDA’s decision …

News
Opdivo

BMS halts Opdivo kidney cancer trial early

July 22, 2015
Research and Development BMS, Bristol-Myers Squibb, European Commission, Kidney cancer, opdivo, renal cell carcinoma

Bristol-Myers Squibb has stopped its Phase III study of its immunotherapy drug Opdivo in people with kidney cancer early after …

News

Pfizer’s Inlyta gains European recommendation

May 28, 2012
Sales and Marketing Inlyta. axitinib, Sutent, renal cell carcinoma

Pfizer’s kidney cancer pill Inlyta has been recommended for use by a European committee. The Committee for Medicinal Products for …

News

FDA approves Pfizer cancer drug Inlyta

January 30, 2012
Sales and Marketing Nexavar, Pfizer, Sutent, rcc, renal cell carcinoma

Pfizer’s kidney cancer drug Inlyta has gained US approval for second line treatment for the disease. Inlyta (axitinib) is now …

News

Latest content

Regeneron and Sanofi’s sBLA for Dupixent accepted by FDA for priority review

September 26, 2023

Acesion Pharma raises €45m series B funding

September 26, 2023

CDC Advisory Committee recommends Pfizer’s RSV vaccine

September 25, 2023

FDA approves Eli Lilly and Boehringer Ingelheim’s Jardiance for chronic kidney disease treatment

September 25, 2023

FDA grants ODD to Nexcella’s NXC-201 as treatment for amyloid light chain amyloidosis

September 22, 2023